US 2011/0003399 A1Published application

Tumor Necrosis Factor-Gamma

AssigneeHuman Genome Sciences, Inc.

InventorsGUO-LIANG YU, JIAN NI, CRAIG A. ROSEN, JUN ZHANG

Life of this patent

Estimating the term…

Loading patent…

Abstract

Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.

Claims20

Dependent claims

An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

(a) a protein whose amino acid sequence consists of amino acid residues −27 to 147 of SEQ ID NO:2;
(b) a protein whose amino acid sequence consists of amino acid residues −26 to 147 of SEQ ID NO:2;
(c) a protein whose amino acid sequence consists of amino acid residues 1 to 147 of SEQ ID NO:2;
(d) a protein whose amino acid sequence consists of amino acid residues 25 to 147 of SEQ ID NO:2;
(e) a protein whose amino acid sequence consists of a portion of SEQ ID NO:2, wherein said portion is at least 30 contiguous amino acid residues in length;
(f) a protein whose amino acid sequence consists of a portion of SEQ ID NO:2, wherein said portion is at least 50 contiguous amino acid residues in length;
(g) a protein whose sequence consists of the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC™ Deposit Number 75927;
(h) a protein whose sequence consists of the amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA contained in ATCC™ Deposit Number 75927;
(i) a protein whose sequence consists of the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC™ Deposit Number 75927;
and
(j) a protein whose sequence consists of the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC™ Deposit Number 75927.

8 more elements

Dependencies are inferred from the claim text.

Facts

Application: 12/879,210Filed 10 Sep 2010
Priority: 7 Nov 1994
Published: 6 Jan 2011
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 51/08
Organic compounds: peptides, e.g. proteins , carriers being peptides, polyamino acids, proteins
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents
C07K 16/241
Against cytokines, lymphokines or interferons: tumor Necrosis Factors
Y02A 50/30
In human health protection, e.g. against extreme weather: against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne…

Family

Application08/461,246Continuation in part · filed 5 Jun 1995
Application09/005,020Continuation in part · filed 9 Jan 1998
Application60/074,047Us provisional application · filed 9 Feb 1998
Application09/131,237Continuation in part · filed 7 Aug 1998
Application09/246,129Continuation in part · filed 8 Feb 1999
Application60/131,963Us provisional application · filed 30 Apr 1999
Application60/132,227Us provisional application · filed 3 May 1999
Application60/134,067Us provisional application · filed 13 May 1999
Application60/180,908Us provisional application · filed 8 Feb 2000
Application60/216,879Us provisional application · filed 7 Jul 2000
Application60/278,449Us provisional application · filed 26 Mar 2001
Application09/899,059Continuation in part · filed 6 Jul 2001
Application60/314,381Us provisional application · filed 24 Aug 2001
Application10/226,294Continuation · filed 23 Aug 2002
Application11/837,082Division · filed 10 Aug 2007
Application12/879,210Division
Application11/837,082Continuation
Application10/226,294Continuation in part
Application11/837,082Continuation in part
US 2002/0090683 A1Published application
US 2002/0150534 A1Published application
US 2003/0027284 A1Published application
US 2003/0129189 A1Published application
US 2007/0297977 A1Published application
US 6,599,719 B2Related patent
US 6,824,767 B2Related patent
US 7,597,886 B2Related patent
US 7,820,798 B2Related patent
US 8,093,363 B2Related patent
US 2011/0003399 A1This patent

From the US filing history. Foreign family members aren’t listed.